TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Aphasia Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction success or failure with desflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of recurrent caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D Imaging Impact on Surgery Planning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Metabolic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression Free Survival at 3 Months (PFS 3)
Endpoint domain: Mortality/survival
Primary endpoint: CTO procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Carbon monoxide diffusion capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety as defined by adverse events, serious adverse events, and dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: biological stress by salivary cortisol secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of acute GvHD grade III and IV
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial high amplitude propagated contractions (HAPC) per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete Renal Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Upper Limb Kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: event rate of all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Quantitative Bone Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intestinal and hepatic lipoprotein production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in pain rating on visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in heart rate (BPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in skin conductance responses (µS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of 89Zr-ABT806 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Reduced Portal Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Physical activity (PA) levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sedentary behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adjusted Mean Monthly Percent of Days Covered With B-blocker
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in Apnea-hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Freedom From Related Serious Adverse Events Within 12 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of grade >= 3 acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Colorectal polyp detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal of small intestinal bacterial overgrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in volumes of organs at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability measured by dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Prognosis in arterial hypertension
Endpoint domain: Mortality/survival
Primary endpoint: risk for future eating disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk for obesity onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline flow-mediated vasodilation at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline 24-hour mean systolic blood pressure at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline Epworth Sleepiness Scale (ESS) at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion of patients with response to CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum prostaglandin E2 level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic nerve activity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bit rate (BR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of intravitreal bevacizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in radiographic healing of periapical tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline on Symptoms of Depression Questionnaire (SDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Total Lean Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neurogenic bowel dysfunction symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in cardiac perfusion as measured by cMRI scan under stress conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in CCS angina score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurement of medroxyprogesterone acetate plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Measurement of estradiol cypionate plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Impact of GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Aided Threshold Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abbreviated Profile of Hearing Aid Benefit (APHAB) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Single Sided Deafness Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion successfully weaned by 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cushman Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Intravital Microscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tuberculin Skin Test conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Warm Sensation (WS) Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heat Pain (HP) Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durable Platelet Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: web creeping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global pain score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in plasma NT-proBNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in communication skill competence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Allograft function impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of hypermetabolic foci of myeloma detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with target lesion failure (TLF)
Endpoint domain: Mortality/survival
Primary endpoint: change in number of sexual partners in the past 3 months
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: change in number of episodes of unprotected sex in the past 3 months
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Visual analog scale-1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual analog scale-2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual analog scale-3
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual analog scale-4
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Mean Gingival Index (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function status at 4 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of adverse reactions following GARDASIL vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical incidence rate of four target organisms
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical incidence rate of C. difficile
Endpoint domain: Adverse events/effects
Primary endpoint: Areas of hyperalgesia and allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Plasma Drug Concentration Versus Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Plasma Drug Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pocket Depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Alveolar Bone Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doppler-echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in whole body and muscle protein breakdown
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decision to seek care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Genetic etiology in Premature ovarian Insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: In-hospital mortality through Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Joint velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprotected sexual intercourse in the past 3 months
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Timing of disappearance of aceto-whitening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Circulatory Lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fetal movements as perceived by the mother
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: outcome measurements
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Mean change in average pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turning performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Concentration (GMC) of Serum Anti-rotavirus Immunoglobulin A (IgA) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Solicited Reactions Within 7 Days of Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Outcome of Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes in peripapillary retinal nerve fiber and macular ganglion cell complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Markers of inflammation and endothelial damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in suicidal behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of perioperative allogenic blood transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Patient's parent/legal guardian global assessment - common cold group
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient's parent/legal guardian global assessment - allergy group
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inflammatory expression related to asthma and corticosteroid response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Child Behavior Check List
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in proportion of households using electric kettles
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Classification accuracy of lesions as benign or malignant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grades of acute radiation induced toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Mean cumulative radiotherapy doses received by the parotid gland
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiological outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of escalated radiotherapy dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of packed red cell units transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Posttraumatic Stress Disorder Checklist (PCL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pulmonary response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Kilocalorie Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of ChAdOx1 nCoV-19 vaccine against COVID-19 disease
Endpoint domain: Mortality/survival
Primary endpoint: Count of Participants Receiving Adjuvant Radiation Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Bladder Pain Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of completion of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Polyunsaturated fatty acid (PUFA) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Contrast material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of wearing off effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Location of the catheter tip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distinction between healthy people and ALS patient subgroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Saliva protein content change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Air Under the Curve (AUC) of Linezolid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Inhibitory Concentration (MIC) of Linezolid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in apnea-hypopnea index (AHI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean Percentage of Time in Therapeutic Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Taken for Aggressive Behaviour to Change to Calm and Tranquil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of patients who give their consent to take part in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total number of questionnaire responses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total number of patients adhering to follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effects on blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual analog score (VAS) pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with endoscopy-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with the classification of gastric conduit ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants with major complications of gastric conduit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with a partial or complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician-Administered PTSD Scale (CAPS-IV) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Oral Intake Scale (FOIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinson's Disease Sleep Scale (PDSS-2) score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Drug-related problems (DRPs)
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed response probability (complete and partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of incomplete treated tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cmax following IV administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf following IV administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 following IV administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient choice of drug
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of patients with detectable KRAS mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of 18F Fluciclovine PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specificity of 18F Fluciclovine PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Experiencing ≥1 Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing ≥1 Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Moderate to Severe COPD Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Early Drop-out Related to Worsening of COPD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clot time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clot Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of an episode of intracranial hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in Fruit and Vegetable (F/V) Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of umbilical cord transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of umbilical cord transplant
Endpoint domain: Adverse events/effects
Primary endpoint: Time to peak concentration of serum bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goal Attainment Scaling change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Continuous Measurement of Heart Arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of a first major cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of severe asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Aspirin Level in Blood (Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nodule detection success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Pain During use of the biopsy needles
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Assessment of safety
Endpoint domain: Adverse events/effects
Primary endpoint: Standardized uptake value (SUV) max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor metabolic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes